Ataxia telangiectasia (A-T) is a rare inherited disorder that primarily affects coordination and balance, along with other body systems. While there is currently no cure for this condition, various treatment approaches aim to manage symptoms, prevent complications, and improve quality of life for affected individuals. Alongside standard supportive care, researchers worldwide are actively investigating new therapies in clinical trials, exploring innovative ways to address the complex challenges posed by this disease.

How Treatment Helps People Living with Ataxia Telangiectasia

When children are diagnosed with ataxia telangiectasia, the focus of treatment shifts immediately toward managing the wide range of symptoms that affect their daily lives. This condition impacts multiple body systems, which means that treatment must address not only the neurological symptoms like difficulty walking and coordinating movements, but also the weakened immune system that makes children vulnerable to infections, and other complications that arise over time. The main goal is to help each child maintain as much independence and comfort as possible, while preventing serious complications that could shorten or diminish quality of life.^[1]

Treatment approaches for A-T depend heavily on the stage of the disease and the specific symptoms each person experiences. Since the condition is progressive and worsens over time, what works in early childhood may need adjustment as a person enters adolescence or young adulthood. For instance, a young child might benefit from physical therapy to maintain balance and muscle strength, while a teenager might require a wheelchair and more intensive respiratory support. Medical professionals typically recommend that families work with teams of specialists who can address the diverse needs that come with this complex condition.^[2]

Currently, medical societies and healthcare guidelines recognize that A-T has no curative treatment available. Instead, approved therapies focus on what doctors call symptomatic and supportive care—meaning treatments that relieve symptoms and support overall health without stopping the underlying disease process. At the same time, researchers around the world are conducting clinical studies to test new medications and therapeutic strategies. Some of these experimental approaches target the genetic and cellular mechanisms that cause A-T, offering hope that future treatments might slow disease progression or improve outcomes in ways that current therapies cannot.^[3]

Standard Treatment Approaches for Ataxia Telangiectasia

The cornerstone of managing ataxia telangiectasia involves addressing each symptom as it appears and preventing complications before they become serious. Because A-T affects so many different body systems, children with this condition typically see multiple healthcare providers, including neurologists who manage movement problems, immunologists who handle immune system deficiencies, and pulmonologists who treat lung complications. This team-based approach ensures that all aspects of the disease receive attention.^[4]

Physical therapy represents one of the most important standard treatments for children with A-T. Since the condition causes progressive ataxia—a term that describes poor coordination and balance—physical therapists work with children to maintain flexibility, strengthen muscles, and improve their ability to perform everyday tasks. Regular physical therapy sessions can help delay the need for mobility aids like wheelchairs, although most individuals with A-T eventually require wheelchair assistance by their teenage years. The exercises and activities are tailored to each child’s abilities and change as the disease progresses.^[2]

Speech therapy is another essential component of standard care. Many children with A-T develop slurred speech and difficulty controlling their breathing, which affects their ability to communicate clearly. Speech therapists teach children techniques to control their breath, articulate words more effectively, and compensate for the coordination problems that affect their mouth and throat muscles. For some children, swallowing becomes difficult as well, and speech therapists can provide strategies to make eating and drinking safer and prevent choking or aspiration of food into the lungs.^[2]

Managing the immune system problems associated with A-T is critical for preventing life-threatening infections. Many people with A-T have what doctors call a combined immunodeficiency, meaning both their B cells and T cells—the immune cells that fight infections—do not work properly. To boost immune function, doctors often prescribe regular injections of immunoglobulins, which are antibodies collected from healthy donors. These immunoglobulin infusions, also called gamma-globulin injections, provide the body with the antibodies it lacks, helping to prevent sinusitis, bronchitis, and pneumonia, which are common in people with A-T.^[5]

Antibiotic treatment plays a major role in managing respiratory infections, which occur frequently in individuals with A-T. When infections develop, prompt treatment with appropriate antibiotics can prevent them from spreading to the lungs and causing chronic lung disease. Some doctors recommend preventive or prophylactic antibiotics for children who experience recurrent infections, although this approach must be balanced against the risk of developing antibiotic-resistant bacteria. The goal is to catch infections early and treat them aggressively before they cause lasting damage to the lungs.^[11]

Children with A-T may also benefit from high-dose vitamins and antioxidants, substances that protect cells from damage caused by unstable molecules called free radicals. The rationale behind this treatment is that oxidative stress—damage caused by these free radicals—may contribute to the neurological decline seen in A-T. While antioxidants have shown some promise in laboratory studies, their effectiveness in human patients is still being evaluated. Nevertheless, some clinicians recommend them as part of a comprehensive treatment plan, particularly when they appear safe and may offer some benefit.^[2]

When cancer develops in people with A-T—which happens in approximately one-third of cases—treatment becomes particularly challenging. The most common cancers are blood-related, such as leukemia (cancer of blood-forming cells) and lymphoma (cancer of immune system cells). Because of the heightened sensitivity to radiation, chemotherapy becomes the primary treatment option. However, even chemotherapy must be adjusted carefully, as some chemotherapy drugs, particularly those that damage DNA in ways similar to radiation, can cause severe side effects. Some reports suggest that certain chemotherapy agents like bleomycin, actinomycin D, and cyclophosphamide should be avoided or used at reduced doses in people with A-T.^[11]

Beta-adrenergic blockers, medications commonly used to treat high blood pressure and heart conditions, may help improve fine motor coordination in some individuals with A-T. These drugs work by blocking certain receptors in the nervous system, which can reduce tremors and involuntary movements. While not effective for everyone, beta-blockers represent one of the few medications that may directly address the movement problems characteristic of A-T. Doctors prescribe them on a case-by-case basis, monitoring for improvement in coordination and any potential side effects.^[11]

Occupational therapy helps children and adults with A-T learn adaptive strategies for daily activities like dressing, eating, and personal care. As coordination problems worsen, occupational therapists recommend assistive devices and modifications to the home environment that promote independence and safety. This might include special utensils for eating, adaptations for using computers and communication devices, or environmental modifications to prevent falls and injuries.^[6]

Nutritional support is often necessary as swallowing difficulties progress. Dietitians work with families to ensure that children receive adequate calories and nutrients, sometimes recommending high-calorie foods or nutritional supplements. In severe cases where swallowing becomes unsafe, doctors may recommend a feeding tube to deliver nutrition directly to the stomach, preventing malnutrition and reducing the risk of aspiration pneumonia, a serious complication that occurs when food or liquid enters the lungs.^[6]

Emerging Treatments Being Tested in Clinical Trials

While standard treatments for ataxia telangiectasia focus on managing symptoms, researchers are exploring new therapies that might address the underlying causes of the disease or slow its progression. Clinical trials represent the pathway through which these experimental treatments are tested for safety and effectiveness. Understanding how clinical trials work helps families appreciate what these studies can and cannot promise.^[2]

Clinical trials typically proceed through three phases. Phase I trials primarily assess safety, determining what dose of a new drug can be given without causing unacceptable side effects. These early trials usually involve small numbers of participants. Phase II trials expand to larger groups and begin to evaluate whether the treatment shows signs of effectiveness—does it improve symptoms, slow disease progression, or achieve other measurable benefits? Finally, Phase III trials compare the new treatment directly against current standard treatments or placebo to determine if it offers meaningful advantages. Only treatments that successfully complete all three phases can be considered for approval by regulatory agencies.^[8]

One of the most promising treatments currently being studied for A-T is N-Acetyl-DL-Leucine, a modified amino acid that has shown potential for improving neurological symptoms. This compound works by affecting the vestibular system, the part of the inner ear and brain that controls balance. Early studies and case reports have suggested that N-Acetyl-DL-Leucine may reduce ataxia and improve coordination in some people with A-T, though larger controlled trials are needed to confirm these findings and understand exactly how well it works. The medication has been tested in various forms of ataxia, and its safety profile appears favorable, with relatively few side effects reported.^[14]

A particularly innovative approach being investigated involves encapsulating dexamethasone, a corticosteroid medication, into red blood cells. This treatment system, known as EryDex, packages dexamethasone sodium phosphate into a patient’s own red blood cells, which are then returned to the body through transfusion. The red blood cells act as tiny delivery vehicles, slowly releasing the medication over time. This method may allow lower doses of dexamethasone to be used compared to traditional oral or intravenous administration, potentially reducing side effects while maintaining therapeutic benefits. Early clinical trials have explored this approach for A-T, though more research is needed to determine its effectiveness and optimal use.^[14]

Dexamethasone itself, a powerful anti-inflammatory medication, has been studied for A-T because the condition involves chronic inflammation and oxidative stress that may contribute to neurodegeneration. By reducing inflammation, dexamethasone might slow the deterioration of brain cells in the cerebellum. However, long-term use of corticosteroids like dexamethasone carries significant risks, including bone thinning, weight gain, increased infection risk, and effects on growth in children. This is why the EryDex system, which may allow lower doses, represents an interesting alternative approach to delivering this medication.^[14]

Bone marrow transplantation, also called hematopoietic stem cell transplantation, has been explored as a potential treatment for the immune system problems in A-T. The theory is that replacing a patient’s defective immune system with healthy stem cells from a donor could restore immune function and reduce susceptibility to infections. However, bone marrow transplantation is a risky procedure that involves intensive chemotherapy to prepare the body for the new cells, and the procedure itself carries significant risks including graft-versus-host disease, where the transplanted immune cells attack the patient’s own tissues. To date, bone marrow transplantation has not become a standard treatment for A-T, and it remains an area of active research to determine if the benefits outweigh the substantial risks.^[14]

Gene therapy represents the most futuristic approach to treating A-T. Since the condition is caused by mutations in the ATM gene, gene therapy aims to introduce a functional copy of this gene into a patient’s cells. Researchers are exploring different methods to deliver the correct gene, including using modified viruses as delivery vehicles. If successful, gene therapy could potentially correct the underlying genetic defect, offering the possibility of slowing or stopping disease progression. However, gene therapy for A-T faces significant technical challenges, including how to safely deliver the gene to the right cells, particularly in the brain, and how to ensure the new gene functions properly over the long term. Clinical trials of gene therapy for A-T are still in very early stages.^[14]

Antioxidant therapies are being investigated more rigorously in clinical trial settings. Beyond simple vitamin supplementation, researchers are testing specific antioxidant compounds designed to be more effective at protecting cells from oxidative damage. One example is desferrioxamine, a medication that binds to iron in the body. Because iron can promote harmful chemical reactions that damage cells, removing excess iron might reduce oxidative stress in A-T. Laboratory studies have shown that desferrioxamine can increase the stability of chromosomes in cells from A-T patients, suggesting it might help protect cells from the DNA damage that characterizes this condition.^[11]

Several clinical trials are investigating therapies aimed at the molecular pathways affected when the ATM protein is absent or not functioning. The ATM protein normally acts as a protein kinase, an enzyme that helps control cell division and coordinates the repair of damaged DNA. When this protein doesn’t work, cells accumulate DNA damage and eventually die, particularly in the cerebellum. Researchers are testing drugs that might compensate for the loss of ATM function by activating related proteins or providing alternative pathways for DNA repair. These approaches are highly technical and still largely in the laboratory or early clinical trial stages.^[8]

Clinical trials for A-T are being conducted at medical centers in the United States, Europe, and other regions around the world. Eligibility for these trials varies depending on the specific study, but most trials have age requirements, disease stage criteria, and other health considerations that determine who can participate. Families can search for active trials through online databases, and many A-T advocacy organizations maintain lists of current research studies recruiting participants. The location of trials can affect participation, as some families may need to travel significant distances to reach trial sites.^[2]

Preliminary results from some clinical trials have shown promise, though it’s important to emphasize that promising early results do not guarantee that a treatment will ultimately prove effective. For example, early studies of N-Acetyl-DL-Leucine reported improvements in balance and coordination measures, with patients experiencing better stability and reduced ataxia symptoms. Similarly, some oxidative stress markers in the blood appeared to improve with antioxidant treatments. However, these findings need confirmation in larger, more rigorous studies before doctors can confidently recommend these treatments as standard care.^[12]

Most Common Treatment Methods

• Physical and Rehabilitation Therapy
  • Physical therapy to maintain flexibility, strengthen muscles, and improve coordination and balance
  • Occupational therapy to develop strategies for daily activities and recommend assistive devices
  • Speech therapy to improve articulation, control breathing, and address swallowing difficulties
• Immune System Support
  • Regular immunoglobulin infusions (gamma-globulin injections) to provide antibodies and prevent infections
  • Antibiotic treatment for respiratory and other infections, including prophylactic antibiotics in some cases
  • Preventive care to minimize exposure to infections
• Medication Management
  • Beta-adrenergic blockers to potentially improve fine motor coordination
  • High-dose vitamins and antioxidants to protect cells from oxidative damage
  • Dexamethasone and experimental EryDex system for anti-inflammatory effects
• Nutritional Support
  • Dietary modifications and high-calorie supplements to maintain adequate nutrition
  • Feeding tubes when swallowing becomes unsafe
  • Monitoring for growth problems and endocrine dysfunction
• Cancer Treatment Adaptations
  • Modified chemotherapy protocols with adjusted doses for individuals sensitive to DNA-damaging agents
  • Avoidance or reduction of radiation therapy due to heightened radiation sensitivity
  • Regular cancer surveillance given increased cancer risk
• Experimental Therapies in Clinical Trials
  • N-Acetyl-DL-Leucine for improving balance and reducing ataxia symptoms
  • Gene therapy approaches attempting to correct the underlying ATM gene mutation
  • Bone marrow transplantation to restore immune system function
  • Novel antioxidant compounds to reduce oxidative stress and protect cells
  • Molecular therapies targeting cellular pathways affected by ATM protein loss